Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of mRNA-1195 Intramuscular Injection in Participants 18 to ≤55 Years of Age With Multiple Sclerosis

NCT06735248 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT06735248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06735248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of mRNA-1195 Intramuscular Injection in Participants 18 to ≤55 Years of Age With Multiple Sclerosis
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
April 16, 2025
Completion date
January 8, 2029
Enrollment
180 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis